These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28107839)

  • 21. Reinitiation of statins after statin-associated musculoskeletal symptoms: a patient-centered approach.
    Brito JP; Montori VM
    Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):243-7. PubMed ID: 23481527
    [No Abstract]   [Full Text] [Related]  

  • 22. Overcoming Challenges With Statin Therapy.
    Spence JD; Dresser GK
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26819251
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacotherapy: Implications of high-dose statin link with incident diabetes.
    Davidson MH
    Nat Rev Cardiol; 2011 Aug; 8(10):543-4. PubMed ID: 21808273
    [No Abstract]   [Full Text] [Related]  

  • 24. New insights into managing symptoms during statin therapy.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care.
    Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G
    Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
    Burstein B; Altobelli KK; Williams K; Cannon CP; Pencina MJ; Sniderman AD; Thanassoulis G
    Circulation; 2017 Nov; 136(19):1860-1862. PubMed ID: 29109198
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonadherence to statins: individualized intervention strategies outside the pill box.
    Lansberg P; Lee A; Lee ZV; Subramaniam K; Setia S
    Vasc Health Risk Manag; 2018; 14():91-102. PubMed ID: 29872306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Preventive-Pill Paradox: How Shared Decision Making Could Increase Cardiovascular Morbidity and Mortality.
    Diprose W; Verster F
    Circulation; 2016 Nov; 134(21):1599-1600. PubMed ID: 27881503
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy.
    Boden WE; McGovern ME
    Am J Cardiol; 2009 Dec; 104(12):1695-6. PubMed ID: 19962477
    [No Abstract]   [Full Text] [Related]  

  • 32. Update on lipids and C-reactive protein in acute and chronic coronary heart disease.
    Jones PH
    Tex Heart Inst J; 2010; 37(3):307-8. PubMed ID: 20548807
    [No Abstract]   [Full Text] [Related]  

  • 33. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin Intolerance From a Clinician's Perspective.
    Whayne TF
    Angiology; 2016 Mar; 67(3):205-7. PubMed ID: 26019266
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy.
    Brown WV
    Clin Pharmacol Ther; 2018 Aug; 104(2):269-281. PubMed ID: 29998536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
    Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Hibi K; Terashima M; Michishita I;
    Nephrology (Carlton); 2012 Sep; 17(7):628-35. PubMed ID: 22708952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature].
    Lucchi T; Vergani C
    G Ital Cardiol (Rome); 2014 Mar; 15(3):149-60. PubMed ID: 24770428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoproteins, stroke and statins.
    Pisciotta L; Bertolini S; Pende A
    Curr Vasc Pharmacol; 2015; 13(2):202-8. PubMed ID: 24188485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
    Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS
    Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.